A New Jersey woman has filed a new Invokana ketoacidosis lawsuit against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, alleging she developed Invokana drug side effects including diabetic ketoacidosis.

Plaintiff Jeannie C. files the Invokana ketoacidosis lawsuit in New Jersey federal court, joining a growing multidistrict litigation (MDL) against the companies.

Jeannie alleges she began taking Invokana (canagliflozin) to treat diabetes and reduce or control her blood sugar level in February 2015. She continued taking the medication through January 2017.

According to the Invokana ketoacidosis lawsuit, due to the improper disclosure of risks with Invokana and due to omissions and misrepresentations of Invokana, Jeannie suffered severe and significant injuries including development of diabetic ketoacidosis.

Jeannie alleges because of Invokana drug side effects, she endured pain and suffering, loss of enjoyment of life, economic loss, emotional distress, and significant medical care and treatment expenses.

The Invokana ketoacidosis lawsuit was filed on multiple counts including manufacturing defect, defective design, failure to warn, breach of express warranty, breach of warranty of fitness for ordinary use, negligence, breach of implied warranty, fraudulent misrepresentation, negligent misrepresentation, fraudulent concealment, and fraud.

Jeannie demands a trial by jury.

Invokana Ketoacidosis Lawsuit Joins MDL

Jeannie’s claim is filed as part of a large multidistrict litigation, or MDL, centered on allegations that Invokana causes serious drug side effects including the development of diabetic ketoacidosis.

Patients who have filed Invokana lawsuits allege that Johnson & Johnson failed to warn them of the risks involved in taking the diabetes drug. Reported Invokana drug side include diabetic ketoacidosis (DKA), pancreatitis, bone fractures, cardiovascular side effects, leg and foot amputations, and kidney problems.

Allegations against the companies accuse them of failing to warn of Invokana drug side effects, failing to conduct proper clinical studies, misrepresenting the benefits and risks of Invokana use, and refusing to disclose pertinent information to the U.S. Food and Drug Administration (FDA).

Invokana Drug Side Effects

According to the FDA, Invokana  is a type-2 diabetes drug prescribed to lower patients’ blood sugar levels in combination with diet and exercise.

Invokana belongs to a class of drugs known as sodium-glucose contransporter-2 (SGLT2) inhibitors. Canagliflozin is sold under the brand names Invokana and in combination with metformin, a diabetes medication, under brand names Invokamet XR and Invokamet.

In a safety announcement made by the FDA in May 2017, the federal agency warned of Invokana drug side effects and increased risks with the type-2 diabetes drug.

According to the FDA’s announcement, “based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.

“We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.”

The Invokana Ketoacidosis Lawsuit is Case No. 3:17-cv-12323-BRM-LHG, in the U.S. District Court for the District of New Jersey. The Invokana Multidistrict Litigation is In re: Invokana (Canagliflozin) Products Liability Litigation, MDL No. 2750, in the U.S. District Court for the District of New Jersey.